The cell numbers of lymphocyte subsets, including CD4+, CD8+, CD3+, and CD56 + T cells, are decreased in patients with advanced cancer, leading to weakened lymphocyte-mediated anti-tumor immune responses [15]. The gene discussed is NCAM1; the disease is neoplasm.